Uploaded October 2026 | Updated November 2026, 2 days ago
Same drug, same shot, and some people lost nearly twice as much weight. A new Mayo Clinic study may point to one reason: the people who responded best to tirzepatide started with the least natural GLP-1. Here's what it found, and what it can't tell us.
IMPORTANT: The tirzepatide results come from a retrospective look at 61 people, not a randomized clinical trial. This is an intriguing idea, not a proven explanation.
IN THIS VIDEO
00:00 Same drug, nearly double the weight loss
00:37 GLP-1 in 60 seconds and the question to keep in mind
01:23 The Mayo study: 483 people and a radioactive breakfast
02:16 Three groups, one "discordant"
02:58 Why Group 3 makes less: gut bacteria and gene activity
03:30 Caveat: the GLP-1 detection limit
03:50 Does low GLP-1 mean more hunger?
04:48 The twist: who lost the most weight 5:33 The hormone replacement idea
06:36 The "super responders"
06:57 The asterisks: what this study can't tell us
08:07 Conflicts of interest
08:29 The dose question: Wegovy 7.2 mg and Lilly's trial
09:48 Where the Mayo study fits (my hypothesis)
10:42 Takeaway: talk to your prescriber
11:14 Obesity may not be one condition
KEY NUMBERS FROM THE STUDY
- 483 adults with obesity were phenotyped (stomach emptying, hunger, gut hormones)
- 130 people (about 27%) emptied fast but had low GLP-1, PYY, and CCK
- 61 people later started tirzepatide
- At 6 months: 21.5% weight loss in the low-GLP-1 group vs 12.1% and 10.8% in the other two groups
SOURCES
Ticho AL, McRae AN, et al. "A subphenotype of obesity with reduced enteroendocrine GLP-1 synthesis and enhanced tirzepatide response." Gastroenterology (author manuscript, Mayo Clinic): pmc.ncbi.nlm.nih.gov/articles/PMC13325417
Lilly higher-dose tirzepatide trial (Phase 2):
clinicaltrials.gov/study/NCT06037252
Wegovy HD (semaglutide 7.2 mg) approval:
biospace.com/press-releases/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss
DISCLAIMER This video is for educational purposes only and is not medical advice. Talk with your doctor or pharmacist before starting, stopping, or changing any medication or dose.
=======================================================
Affiliate Links (I earn commission for qualifying purchases)
Gruns: grns.sjv.io/AgoLV7
========================================================
Social Links
TikTok: tiktok.com/@thee_rmz
Instagram: instagram.com/thee_rmz
========================================================
DISCLAIMER: No information provided here is to be construed as medical advice. Always consult with a licensed medical provider for medical advice.
#glp1 #zepbound #mounjaro #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #beforeandafter #beforeandafterweightloss
Same drug, same shot, and some people lost nearly twice as much weight. A new Mayo Clinic study may point to one reason: the people who responded best to tirzepatide started with the least natural GLP-1. Here's what it found, and what it can't tell us.
IMPORTANT: The tirzepatide results come from a retrospective look at 61 people, not a randomized clinical trial. This is an intriguing idea, not a proven explanation.
IN THIS VIDEO
00:00 Same drug, nearly double the weight loss
00:37 GLP-1 in 60 seconds and the question to keep in mind
01:23 The Mayo study: 483 people and a radioactive breakfast
02:16 Three groups, one "discordant"
02:58 Why Group 3 makes less: gut bacteria and gene activity
03:30 Caveat: the GLP-1 detection limit
03:50 Does low GLP-1 mean more hunger?
04:48 The twist: who lost the most weight 5:33 The hormone replacement idea
06:36 The "super responders"
06:57 The asterisks: what this study can't tell us
08:07 Conflicts of interest
08:29 The dose question: Wegovy 7.2 mg and Lilly's trial
09:48 Where the Mayo study fits (my hypothesis)
10:42 Takeaway: talk to your prescriber
11:14 Obesity may not be one condition
KEY NUMBERS FROM THE STUDY
- 483 adults with obesity were phenotyped (stomach emptying, hunger, gut hormones)
- 130 people (about 27%) emptied fast but had low GLP-1, PYY, and CCK
- 61 people later started tirzepatide
- At 6 months: 21.5% weight loss in the low-GLP-1 group vs 12.1% and 10.8% in the other two groups
SOURCES
Ticho AL, McRae AN, et al. "A subphenotype of obesity with reduced enteroendocrine GLP-1 synthesis and enhanced tirzepatide response." Gastroenterology (author manuscript, Mayo Clinic): pmc.ncbi.nlm.nih.gov/articles/PMC13325417
Lilly higher-dose tirzepatide trial (Phase 2):
clinicaltrials.gov/study/NCT06037252
Wegovy HD (semaglutide 7.2 mg) approval:
biospace.com/press-releases/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss
DISCLAIMER This video is for educational purposes only and is not medical advice. Talk with your doctor or pharmacist before starting, stopping, or changing any medication or dose.
=======================================================
Affiliate Links (I earn commission for qualifying purchases)
Gruns: grns.sjv.io/AgoLV7
========================================================
Social Links
TikTok: tiktok.com/@thee_rmz
Instagram: instagram.com/thee_rmz
========================================================
DISCLAIMER: No information provided here is to be construed as medical advice. Always consult with a licensed medical provider for medical advice.
#glp1 #zepbound #mounjaro #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #beforeandafter #beforeandafterweightloss










